Literature DB >> 20223720

Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature.

Anita D'Souza1, Jon Wilson, Sudipto Mukherjee, Ishmael Jaiyesimi.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by the John Cunningham (JC) virus, a DNA papovavirus. It is usually associated with conditions causing profound immunodeficiency, classically seen in patients with HIV/AIDS. Since its first description in 1958, PML has also been associated with various lymphoproliferative malignancies, including chronic lymphocytic leukemia (CLL). With the use of newer chemotherapeutic agents such as the purine analogue fludarabine and various monoclonal antibodies in the treatment of CLL, more cases of PML are being described. In this article, we describe 3 patients encountered in our clinical practice having CLL and PML infection. All three patients had received fludarabine and rituximab at some point during the course of their chemotherapy. We provide these cases with a review of the literature.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20223720     DOI: 10.3816/CLML.2010.n.009

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  15 in total

1.  Late relapse of progressive multifocal leucoencephalopathy postallogenic transplant in a young patient with CLL.

Authors:  Ana Sanchez-Quintana; Joaquín Breña-Atienza; Carmen Marrero-Santos; Luis Alvarez-Acosta
Journal:  BMJ Case Rep       Date:  2013-08-05

2.  Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab.

Authors:  Luís Isidoro; Paula Pires; Luís Rito; Gustavo Cordeiro
Journal:  BMJ Case Rep       Date:  2014-01-08

Review 3.  Rituximab in chronic lymphocytic leukemia.

Authors:  Danelle F James; Thomas J Kipps
Journal:  Adv Ther       Date:  2011-07-02       Impact factor: 3.845

4.  Cooperative roles of NF-κB and NFAT4 in polyomavirus JC regulation at the KB control element.

Authors:  Hassen S Wollebo; Sonia Melis; Kamel Khalili; Mahmut Safak; Martyn K White
Journal:  Virology       Date:  2012-06-30       Impact factor: 3.616

Review 5.  Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.

Authors:  S A Misbah
Journal:  Clin Exp Immunol       Date:  2017-03-27       Impact factor: 4.330

Review 6.  Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML).

Authors:  Amir Khalili; Michael Craigie; Martina Donadoni; Ilker Kudret Sariyer
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-27       Impact factor: 4.147

Review 7.  Neurologic Emergencies in the Patients With Cancer.

Authors:  Andrew L Lin; Edward K Avila
Journal:  J Intensive Care Med       Date:  2016-07-09       Impact factor: 3.510

Review 8.  Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes.

Authors:  Jan Lycke
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

9.  Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia.

Authors:  Paolo Strati; Joon H Uhm; Timothy J Kaufmann; Chadi Nabhan; Sameer A Parikh; Curtis A Hanson; Kari G Chaffee; Timothy G Call; Tait D Shanafelt
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

10.  Not All Strokes Are Strokes An Example of Diagnostic Confirmation Bias.

Authors:  Melanie Dani; Sophie Bowen-Carpenter; Patrick J McGown
Journal:  Eur J Case Rep Intern Med       Date:  2019-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.